NeuroMetrix Is Better Positioned After Share Raise

Yesterday morning, NeuroMetrix (NURO) announced that the company was able to raise more than $10,000,000 by offering 10,500,000 shares at $1 per share, plus warrants. While this was more than 10% lower than the prior day's closing price, it should comfort long term investors that the company now has what should be enough money to manage through 2-3 years of losses until the company's primary product, NC-Stat DPN Check, can reach a critical mass in sales. Additionally, the fact that management was able to convince a new round of investors that their product can be successful in the market place bodes well for the company.

The potential for a dilutive capital raise has been one major hurdle for investors looking at the company prior to today's announcement. However, I think that the primary focal point for all investors is the chance of success of the company's primary product, NC-Stat DPNCheck.